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Abstract p14ARF tumour suppressor stabilises and activates
p53 by directly interacting with (H)Mdm2 [(human) murine
double minute 2 homologue] and inhibiting its E3 ubiquitin li-
gase activity. Here we demonstrate that p14ARF promotes ac-
cumulation of (H)Mdm2 conjugated to the small ubiquitin-like
protein SUMO-1. Mutational analysis demonstrated that the
N-terminus of Mdm2 is a target for p14ARF-mediated
SUMO conjugation. SUMO modi¢cation requires residues
2^14 in p14ARF that interact with (H)Mdm2 and residues
82^101 in exon 2 involved in nucleolar localisation of
p14ARF. These data suggest a novel role for p14ARF as a
regulator of activity of (H)Mdm2, which could be related to
its tumour suppressing activities. 5 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The product of the murine double minute 2 homologue
(Mdm2) oncogene plays a vital role in regulation of the stabil-
ity and activity of the p53 tumour suppressor protein. Initial
genetic studies demonstrated that a critical role of Mdm2 is to
negatively regulate the growth suppressing e¡ects of p53 [1,2].
Biochemical and biological studies showed that Mdm2 can act
as a ubiquitin E3 ligase [3], promoting ubiquitylation and
proteasomal degradation of p53 [4^6]. Mdm2 can also regu-
late its own stability by promoting auto-ubiquitylation [7^9].
In mammals the INK4K-P14ARF locus encodes two di¡er-
ent cell cycle inhibitors (p16INK4K and p14ARF) by alterna-
tive splicing [10,11]. The observation that p14ARF null mice
develop tumours at an early stage and the requirement of
wild-type p53 for p14ARF to induce G1 cell cycle arrest
strongly suggest that p14ARF is acting upstream of p53 as
a tumour suppressor [12].
At the molecular level, p14ARF has been shown to interfere
with the ability of Mdm2 to suppress the stability and activity
of p53 [13^16]. P14ARF directly interacts with (H)Mdm2
(Hdm2, human homologue of Mdm2), inhibiting ubiquityla-
tion and resulting in p53 accumulation and induction of the
p53 response [9,17,18].
Recently, the Mdm2 protein was demonstrated to become
conjugated to small ubiquitin-like protein SUMO-1. This
modi¢cation was proposed to a¡ect the stability of Mdm2
and its ability to promote ubiquitylation of p53 [19]. SUMO
is conjugated to protein substrates in a manner that is mech-
anistically similar to that of ubiquitin. In the case of SUMO,
however, the SUMO activating enzyme (SAE) is a hetero-
dimer of SAE1 and SAE2 and the E2 is Ubc9 (reviewed in
[20,21]).
Here we demonstrate a role for p14ARF in SUMO-1 con-
jugation of (H)Mdm2. In the absence of p14ARF, (H)Mdm2
is modi¢ed by SUMO-1 at a very low level. However, in the
presence of p14ARF, the levels of (H)Mdm2 conjugated to
SUMO-1 increase dramatically. Mutational analysis demon-
strated that the N-terminus of Mdm2 can be used for
p14ARF-mediated SUMO-1 conjugation and that binding
of p14ARF to (H)Mdm2 as well as sequences in exon 2 of
p14ARF are required for this e¡ect. These data propose a
novel role for the p14ARF tumour suppressor as a regulator
of SUMO conjugation, which may be related to its growth
suppressing activities.
2. Materials and methods
2.1. Materials
Human and mouse Mdm2 were detected using the 4B2 mouse
monoclonal antibody [22]. MG132 was purchased from Calbiochem.
Plasmids used in this study are described elsewhere [18,23].
2.2. Transfections
H1299 cells were transfected with calcium-phosphate method as
described before [18]. Where indicated 7 Wg of H(M)dm2, 7 Wg of
p14ARF and 2 Wg of His6-SUMO-1 expressing plasmids were used.
2.3. Puri¢cation of His6-SUMO-1 conjugates
Thirty-six hours post-transfection cells were harvested and His6-
SUMO-1 conjugates were puri¢ed as described before [18,23]. Twenty
percent of cells were used for NP-40 lysis and Western blotting was
performed as described in [18].
2.4. In vitro SUMO-1 conjugation assay
Wild-type Mdm2 or Mdm2 deletion mutants were expressed in
vitro using the TnT T7 Coupled Wheat Germ Extract System from
Promega according to manufacturer’s instructions. One Wl of 35S-me-
thionine-labelled protein was incubated in a 10 Wl reaction with puri-
¢ed components required for SUMO modi¢cation and analysed by
phosphorimaging as described [24].
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3. Results
3.1. Expression of p14ARF promotes accumulation of
SUMO-1 conjugated Hdm2 in vivo
Recently, it was reported that the Hdm2 protein could be
modi¢ed with the ubiquitin-like protein SUMO-1 with conse-
quences for the stability and E3 ubiquitin ligase activity of
Hdm2 towards p53 [19]. We have recently demonstrated
that expression of the p14ARF tumour suppressor stabilises
Hdm2 without a¡ecting its auto-ubiquitylation activity [18].
Therefore, we investigated the e¡ect of p14ARF on SUMO-1
conjugation of Hdm2. H1299 cells (p53 null) were transfected
with expression constructs for Hdm2, p14ARF and a His6
version of SUMO-1. Cells were harvested and a fraction
was used to monitor expression of Hdm2 by Western blotting.
The remaining cells were lysed in guanidinium^HCl and His6-
SUMO-1 conjugated proteins were puri¢ed using Ni2þ-aga-
rose beads. Proteins eluted from the Ni2þ beads were analysed
by Western blotting with 4B2 anti-Hdm2 monoclonal anti-
body to detect SUMO-1-Hdm2 conjugation.
Hdm2 expression generated species of 75 and 90 kDa, both
of which were stabilised by expression of p14ARF (Fig. 1A,
left panel). SUMO-1 modi¢ed Hdm2 was detected when
p14ARF was co-expressed, but not when Hdm2 was ex-
pressed alone (Fig. 1A, right panel). The major form of
SUMO-1-Hdm2 migrates as a 120 kDa species, which is con-
sistent with the attachment of one or two SUMO-1 moieties.
Furthermore, more slowly migrating forms of SUMO-1-
Hdm2 were also detected, which could represent SUMO-1-
Hdm2 with additional post-translational modi¢cations. Alter-
natively, the slower migrating forms could result from the
addition of multiple SUMO-1 molecules. It is worth noting
that the His6-SUMO-1 conjugated eluates do not contain any
Hdm2 species of Mr 90 kDa, which was the reported size of
Hdm2 after conjugation to a single SUMO-1 moiety [19].
It was previously reported that a single point mutation in
the ring ¢nger domain of Hdm2 (K446R) prevented SUMO-1
conjugation in vitro and in vivo [19]. However, we found that
expression of p14ARF could also promote SUMO-1 conjuga-
tion of the K446R Hdm2 mutant as e¡ectively as wild-type
Hdm2 (Fig. 1B, lower panel). To our surprise expression of
the K446R mutant generated the 75 and 90 kDa species ob-
served with wild-type Hdm2 and expression of p14ARF sta-
bilised both species (Fig. 1B, upper panel). This is in direct
contrast to previous observations which reported that K446R
Hdm2, de¢cient for SUMO-1 conjugation, migrates as a sin-
gle 75 kDa species which was thought to represent the un-
modi¢ed Hdm2. Critically, bacterially expressed Hdm2, which
is not SUMO conjugated, also migrates as two species of
75 and 90 kDa (Fig. 1B, upper panel).
Detection of SUMO-1-Hdm2 after expression of p14ARF
could be due to either the stabilising e¡ect of p14ARF on the
levels of Hdm2, or that p14ARF plays an active role in the
SUMO pathway. To distinguish between these two possibil-
ities the mouse homologue of Hdm2 (Mdm2) whose stability
Fig. 1. A: Co-expression of p14ARF results in accumulation of
SUMO-1 conjugated Hdm2. H1299 cells were transfected with
Hdm2 alone (7 Wg) or with p14ARF (7 Wg) expression constructs.
In all transfections 2 Wg of His6-SUMO-1 expression construct was
included. Thirty-six hours post-transfection cells were harvested and
analysed for total Hdm2 levels (left panel) or SUMO-1-Hdm2 (right
panel) by Western blotting using the 4B2 anti-Hdm2 monoclonal
antibody (1 Wg/ml) as described in Section 2. B: P14ARF promotes
SUMO-1 conjugation of the K446R Hdm2 mutant. Wild-type
Hdm2 or the K446R mutant were expressed in the absence or pres-
ence of p14ARF and cell extracts were analysed as described above.
Fifty ng of bacterial expressed Hdm2 [9] were also analysed by
Western blotting.
Fig. 2. P14ARF-mediated accumulation of SUMO-1-Hdm2 is not
due to the stabilising e¡ect of p14ARF on Hdm2. H1299 cells were
transfected with the indicated constructs as described before.
MG132 proteasome inhibitors were used for 3 h at 30 WM. Cells
were harvested and analysed by Western blotting as described in
Fig. 1.
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is not signi¢cantly a¡ected by p14ARF was employed. Ex-
pression of p14ARF did not a¡ect the stability of Mdm2
but increased the amount of SUMO-1-Mdm2 detected (Fig.
2, left panel). In another experiment (Fig. 2, right panel) cells
expressing Hdm2 were treated with MG132 proteasome inhib-
itor in the absence of p14ARF. Under these conditions Hdm2
protein is elevated to the same level as that observed in the
presence of p14ARF. While p14ARF expression resulted in
detection of SUMO-1-Hdm2, proteasome inhibitors did not
stimulate formation of SUMO-1 modi¢ed Hdm2. Therefore,
it appears that expression of p14ARF promotes accumulation
of SUMO-1-(H)Mdm2 conjugates and it is not due to the
stabilising e¡ect of p14ARF on Hdm2.
3.2. The N-terminus of Mdm2 is a target for p14ARF-mediated
SUMO-1 conjugation
To identify regions in (H)Mdm2 required for SUMO-1
modi¢cation in vivo, Mdm2 deletion mutants were expressed
in H1299 cells either in the absence or presence of p14ARF
and lysates were analysed for total Mdm2 protein levels or
His6-SUMO-1-Mdm2 isolated on Ni2þ beads as before. The
p14ARF binding domain on Mdm2 is located between resi-
dues 212^244 [9]. The v26 mutant (residues 1^152) lacks the
p14ARF binding site and no SUMO-1 conjugation was ob-
served. Mdm2 deletion mutants v18 (residues 1^272) and v11
(residues 1^342) contain the p14ARF binding site and both
are conjugated to SUMO-1 in the presence of p14ARF (Fig.
3A). A similar mutational analysis was performed using an in
vitro Mdm2 SUMO-1 conjugation assay. 35S-labelled Mdm2
was incubated with puri¢ed SAE, Ubc9 and SUMO-1 as de-
scribed [24]. Mdm2 is modi¢ed with SUMO-1 only when all
the necessary components are included (Fig. 3B). Using this
assay, Mdm2 deletion mutants were analysed for their ca-
pacity to be modi¢ed by SUMO-1. This analysis also demon-
strated that the N-terminal 212 residues of Mdm2 are a target
for SUMO-1 conjugation (Fig. 3C). The 1^134 Mdm2 dele-
tion mutant was not conjugated to SUMO-1, suggesting that
lysine residues between amino acids 134 and 212 in Mdm2 are
sites for SUMO-1 conjugation, although this does not exclude
the possibility that the mutant is de¢cient in its interaction
with modi¢cation enzymes such as Ubc9. Analysis of point
mutations in this area did not provide clear evidence for in-
volvement of a single lysine residue in SUMO-1 conjugation.
P14ARF was also added to the in vitro SUMO-1 conjugation
assay either by co-expression in vitro with Mdm2 or by add-
ing bacterially expressed p14ARF. Neither of these additions
altered SUMO-1 conjugation of Mdm2. While the in vitro
SUMO-1 assay may be lacking factors present in vivo the
presented data from the in vivo and in vitro analysis demon-
strate that the N-terminus of Mdm2 can be used as a sub-
strate for SUMO-1 conjugation.
3.3. Sequences in exon 2 of p14ARF are required for SUMO-1
conjugation of H(M)dm2
To identify the region of p14ARF required for enhance-
ment of SUMO modi¢cation of (H)Mdm2 in vivo, previously
described p14ARF deletion mutants were employed [18,25].
The v2^14 p14ARF mutant was shown to be de¢cient for
(H)Mdm2 binding, whereas the v82^101 p14ARF mutant
was defective for nucleolar localisation of p14ARF [26,27].
While wild-type p14ARF stabilised Hdm2 and promoted
SUMO-1 conjugation, the v2^14 p14ARF mutant had no
e¡ect either on Hdm2 levels or the extent of SUMO-1 con-
jugation (Fig. 4). Although the v82^101 p14ARF could sta-
bilise Hdm2, it was unable to induce SUMO-1 conjugation of
Hdm2. To demonstrate that lack of SUMO-1 conjugation was
Fig. 3. A: The N-terminus of Mdm2 can be used for p14ARF-
mediated SUMO-1 conjugation in vivo. Mdm2 deletion mutants
were expressed in H1299 cells in the absence or presence of
p14ARF and analysed as before. v26: 1^152, v18: 1^272, v11: 1^
342. B: Mdm2 is SUMO-1 modi¢ed in vitro. Wild-type Mdm2 was
expressed in vitro using wheat germ lysates and used in the in vitro
SUMO-1 conjugation assay as described in Section 2. In one case
GST-SUMO-1 was used in the in vitro reaction. C: The N-terminus
of Mdm2 is SUMO-1 modi¢ed in vitro. Wild-type Mdm2 and
Mdm2 deletion mutants were expressed in vitro and used in the in
vitro SUMO-1 conjugation assay as above.
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not a consequence of Hdm2 stabilisation, v11 Mdm2 (residues
1^342), whose protein levels do not alter upon co-expression
of p14ARF, was employed. Only co-expression of wild-type
p14ARF could promote SUMO-1 conjugation of the Mdm2
mutant whereas neither the v2^14 nor the v82^101 p14ARF
mutants had any e¡ect on this modi¢cation (Fig. 4). These
results demonstrate that both binding of p14ARF to
H(M)dm2 and sequences in exon 2 of p14ARF are necessary
for the ability of p14ARF to promote SUMO-1 conjugation
of H(M)dm2.
4. Discussion
Here we demonstrate that p14ARF can promote accu-
mulation of SUMO-1 conjugated (H)Mdm2. Three pieces of
evidence support this statement: (1) While expression of
p14ARF stabilised Hdm2 and led to the accumulation of
SUMO-1-Hdm2, proteasome inhibitors failed to do so, de-
spite the fact that Hdm2 was stabilised to very similar protein
levels as with co-expression of p14ARF. (2) Co-expression of
p14ARF with wild-type Mdm2 or Mdm2 deletion mutants
lacking the C-terminus did not alter their protein levels but
generated SUMO-1 conjugated species. (3) A p14ARF dele-
tion mutant (v82^101) which could stabilise Hdm2, was de¢-
cient in generating SUMO-1-Hdm2 species. All these data
strongly support an active role for p14ARF in accumulation
of (H)Mdm2 conjugated to SUMO-1.
Previous studies reported that Hdm2 protein migrates as a
75 and 90 kDa species and that the 90 kDa species is Hdm2
modi¢ed with a single SUMO-1 moiety [19]. However, His6-
SUMO-1 conjugates puri¢ed through Ni2þ beads did not con-
tain any 90 kDa Hdm2 species, despite the fact that this form
of Hdm2 is constitutively expressed in mammalian cells. The
major form of His6-SUMO-1-Hdm2 puri¢ed with this ap-
proach migrated as a 120 kDa band suggesting the attachment
of one or two SUMO-1 moieties on Hdm2. Furthermore, the
K446R Hdm2 mutant, which was reported to be de¢cient for
SUMO conjugation generated the same 75 and 90 kDa spe-
cies, as wild-type Hdm2. More importantly, bacterially ex-
pressed Hdm2, which is not SUMO modi¢ed, generated the
same 75 and 90 kDa species, observed in mammalian cells.
These data demonstrate that the 90 kDa Hdm2 species is not
a SUMO modi¢ed form and that the major SUMO-Hdm2
form migrates as a 120 kDa species.
Mutational analysis on p14ARF demonstrated that both
binding to (H)Mdm2 and sequences in exon 2 of p14ARF
are necessary for SUMO-1 conjugation of (H)Mdm2. Muta-
tional analysis of Mdm2 did not provide evidence for the
requirement of a single lysine residue in SUMO-1 conjugation
although the N-terminus of Mdm2 can be used as a substrate
for p14ARF-mediated SUMO-1 modi¢cation. Accumulation
of SUMO-1 conjugated (H)Mdm2 mediated by p14ARF
could result from either activation/recruitment of an E3-
SUMO ligase or inhibition of a SUMO-speci¢c protease.
The E3 ubiquitin ligase activity of (H)Mdm2 lies in the ring
¢nger domain at the C-terminus of the protein [7^9]. The
observation that p14ARF could promote SUMO conjugation
of Mdm2 deletion mutants lacking the ring ¢nger domain
suggests that the E3 ubiquitin ligase activity of (H)Mdm2 is
dispensable for p14ARF-mediated SUMO conjugation.
Overexpression of p14ARF changes the subcellular local-
isation of (H)Mdm2 by promoting its localisation to the nu-
cleolus, which could be related with the ability of p14ARF to
promote SUMO conjugation on (H)Mdm2 [28].
Expression of p14ARF protects p53 from (H)Mdm2-medi-
ated ubiquitylation but has no e¡ect on the auto-ubiquityla-
tion activity of (H)Mdm2 [18]. As v82^101 p14ARF mutant
could stabilise H(M)dm2 but was de¢cient in promoting
SUMO-1 conjugation, this suggests that SUMO-1 modi¢ca-
tion of (H)Mdm2 does not interfere with the activity of
(H)Mdm2 to regulate its own ubiquitylation and proteasomal
degradation.
The correlation, between the di¡erential role of p14ARF on
the E3 ubiquitin ligase activity of (H)Mdm2 towards p53 and
towards itself, and p14ARF-mediated SUMO conjugation of
(H)Mdm2 could now be addressed along with the e¡ect of this
modi¢cation on the ability of (H)Mdm2 to down regulate the
growth suppressing e¡ects of p53.
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